Variable | n | Sarcopenia EWGSOP2 | Sarcopenia FNIH | ||||
Yes n=13 | No n=276 | P value | Yes n=8 | No n=281 | P value | ||
Age (years), mean±SD | 289 | 62±8.0 | 59±11.4 | 0.35 | 66±8.4 | 59±11.3 | 0.12 |
Sex, n (%) | 289 | 0.26 | 0.21 | ||||
Female | 9 (69.2) | 221 (80.1) | 5 (62,5) | 225 (80.7) | |||
Male | 4 (30.8) | 55 (19.9) | 3 (37.5) | 56 (20.0) | |||
Height (m), mean±SD | 289 | 1.7±0.1 | 1.7±0.1 | 0.13 | 1.6±0.1 | 1.7±0.1 | 0.005 |
Weight (kg), mean±SD | 289 | 66.5±8.7 | 75.3±13.9 | 0.02 | 77.4±16.2 | 74.8±13.8 | 0.61 |
BMI (kg/m²), mean±SD | 289 | 23.0±2.6 | 27.1±4.5 | <0.0001 | 30.5±4.9 | 26.9±4.4 | 0.02 |
Fat mass (%), mean±SD | 289 | 38.3±6.7 | 38.8±7.5 | 0.79 | 44.2±9.5 | 38.6±7.3 | 0.04 |
DAS28CRP, median (IQR) | 285 | 2.8 (1.1) | 2.1 (1.3) | 0.12 | 2.7 (1.1) | 2.1 (1.3) | 0.08 |
CRP (mg/L), median (IQR) | 274 | 3.3 (6.9) | 2.2 (3.2) | 0.24 | 3.3 (8.3) | 2.2 (3.4) | 0.41 |
Disease duration (years), median (IQR) | 289 | 22 (10) | 9 (12) | 0.002 | 15.5 (14) | 9 (13) | 0.19 |
bDMARDs, n (%) | 280 | 9 (69.2) | 121 (45.3) | 0.09 | 6 (75.0) | 124 (45.6) | 0.15 |
cDMARDs, n (%) | 280 | 9 (69.2) | 181 (67.8) | 1.0 | 5 (62.5) | 185 (68.0) | 0.71 |
Glucocorticoids current, n (%) | 280 | 11 (84.6) | 136 (50.9) | 0.02 | 7 (87.5) | 140 (51.5) | 0.07 |
Cumulative prednisone dose (g), median (IQR) | 275 | 36.9 (63.6) | 9.6 (20.4) | 0.0003 | 29.4 (48.2) | 9.9 (20.6) | 0.06 |
Current smoking, n (%) | 288 | 3 (23.1) | 56 (20.4) | 0.52 | 1 (12.5) | 58 (20.7) | 1.0 |
Regular alcohol consumption, n (%) | 289 | 0 | 2 (0.7) | 1.0 | 0 | 2 (0.7) | 1.0 |
≥1 × sports/ week, n (%) | 285 | 7 (53.9) | 194 (70.0) | 0.23 | 3 (37.5) | 194 (70.0) | 0.11 |
Sunlight exposure, n (%) | 289 | 0.46 | 0.49 | ||||
<30 min/ day | 8 (61.5) | 141 (51.1) | 3 (37.5) | 146 (52.0) | |||
≥30 min/ day | 5 (38.5) | 135 (48.9) | 5 (62.5) | 135 (48.0) | |||
Nutrition, n (%) | 286 | 1.0 | 1.0 | ||||
vegetarian/vegan diet | 1 (7.7) | 27 (9.9) | 0 | 28 (10.1) | |||
mixed diet | 12 (92.3) | 246 (90.1) | 8 (100) | 250 (89.9) | |||
HAQ (0–3), median (IQR) | 289 | 1.5 (1.3) | 0.5 (1.2) | 0.01 | 1.6 (2.0) | 0.5 (1.3) | 0.14 |
BRAF-NRS Fatigue (0–10), mean±SD | 289 | 4.4±2.9 | 4.4±2.4 | 0.98 | 4.6±3.2 | 4.4±2.4 | 0.79 |
ABC-scale (0–100), median (IQR) | 289 | 88.2 (36.3) | 90.5 (22.2) | 0.07 | 70.0 (43.5) | 90.0 (22.5) | 0.21 |
IPAQ total MET(min/week), median (IQR) | 289 | 1470 (2670) | 4246 (4884) | 0.04 | 3432 (2486) | 4158 (4974) | 0.35 |
Bold values: p<0.05 significant.
ABC-scale, Activities-specific Balance Confidence Scale; bDMARDS, biological disease-modifying antirheumatic drugs; BMI, body mass index; BRAF-NRS, Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scale; CRP, C reactive protein; DAS28CRP, Disease Activity Score of 28 joints including C reactive protein; EWGSOP2, European Working Group on Sarcopenia in Older People; FNIH, Foundation for the National Institutes of Health; HAQ, Health Assessment Questionnaire; IPAQ, International Physical Activity Questionnaire; MET, metabolic equivalent; MTX, Methotrexate; RA, rheumatoid arthritis.